No Data
No Data
SA Asks: Which Weight-loss Stocks Should Investors Be Watching?
J.P. Morgan Predicts up to 210% Gains for These 2 'Strong Buy' Stocks
Structure Therapeutics (NASDAQ:GPCR): Analysts Say This GLP-1 Stock Can Rise 130%
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
Buy Rating on Structure Therapeutics' GSBR-1290 for Non-T2D Obesity Potential
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.What Happened: JPMorgan
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.